# Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

> **NCT05605470** · PHASE2 · COMPLETED · sponsor: **Technovalia, Pty Ltd** · enrollment: 150 (actual)

## Conditions studied

- COVID-19, SARS CoV 2 Infection

## Interventions

- **BIOLOGICAL:** ChulaCov19 BNA159 vaccine (50 mcg)
- **BIOLOGICAL:** Pfizer/BNT vaccine (30 mcg)
- **BIOLOGICAL:** COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)

## Key facts

- **NCT ID:** NCT05605470
- **Lead sponsor:** Technovalia, Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-19
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-11-18
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605470, "Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05605470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*